Isn't it amazing when trials and tribulations come, you feel there's no way out, then with just a moment things can change and you realize with God there is no doubt.
Just a few days ago I made all sorts of plans, made goals to improve my health & have been excited about doing so since. Then last night right before it was time to get my Wii Fit on, Bryan told me some really exciting news: the FDA approved the first drug for Lupus in over 52 years yesterday! <3
This is signficant for me being that in the past five months I was removed from all my Lupus treatment medication because it was having adverse affects. Until now there has been no other hope, so today I rejoice. I was very pumped to hear the news but I really didn't put much thought into it at the time...
then, this morning I woke up to an email introducing me to the news of BENLYSTA and reality sank in.
:)
As soon as I put it all in God's hands things began to work out. It took me giving up my "I have to do it" attitude for change to come. I let him have the burden that weighed hard on my shoulders & with just a matter of time things started looking up again.
I know this post will not mean much to many people, being that sometimes it takes experience to really understand. But, my point is have faith in God, know that he is there, and one door is never shut if another one will not be opened.
------------------------------------------------------------------
Lupus Foundation of America Applauds FDA's Decision to Approve Benlysta®
First new treatment for lupus in more than 52 years
Watch a message from Sandra C. Raymond, LFA President and CEO. |
Watch Gary S. Gilkeson, MD, Chair of LFA Medical-Scientific Advisory Council, and Joan T. Merril, MD, LFA Medical Director, speak about what a new treatment may mean for the future of lupus patients. |
Watch Kelly Jean Drury speak about what a new treatment means to her as someone with lupus. |
(Washington, DC, March 9, 2011) Today, the U.S. Food and Drug Administration (FDA) approved the drug, BENLYSTA®, for the treatment of lupus, an autoimmune disease.
Sandra C. Raymond, President and Chief Executive Officer of the Lupus Foundation of America (LFA), has issued the following statement regarding the FDA’s decision:
“This is a historic day for the millions of people with lupus and their families around the world who have waited more than 52 years for a treatment breakthrough for lupus. We at the LFA applaud the FDA’s decision to approve BENLYSTA®. BENLYSTA is the first drug ever to be specifically developed to treat lupus, and is a significant first step toward reaching our goal of developing an arsenal of new, safe, effective, and tolerable treatments. Today marks the beginning of a new era of improved diagnosis, prevention, and treatment for the disease.
“The LFA wishes to thank the physicians, researchers, industry leaders, and the many study volunteers who made this day possible. We also extend a special thank you to BENLYSTA®’s developers, the staff of Human Genome Sciences and GlaxoSmithKline, who have long been committed to the research and development process. These efforts will go a long way in elevating the profile of this disease that remains a significant national public health problem.
“There are a number of pioneering biotechnology and pharmaceutical companies, involved in the research and development of new treatments for lupus, and our hope is that today’s decision will further stimulate additional companies to invest in new therapies for lupus. To build on this momentum and encourage the development of new treatments, the LFA has launched new initiatives that help to strengthen clinical trials. These programs include the launch of a Web-based program designed to train clinical investigators on the instruments used in trials. As well, the LFA recently implemented the LFA Lupus Research Registry which enables individuals to be notified about new clinical trials in their geographic area. The Registry is part of the LFA’s Center for Clinical Trials Education.
“The LFA also is partnering with key stakeholders from industry, government, and the scientific community to evaluate data from previous lupus clinical trials with the goal to improve the design of future studies."
Sandra C. Raymond, President and Chief Executive Officer of the Lupus Foundation of America (LFA), has issued the following statement regarding the FDA’s decision:
“This is a historic day for the millions of people with lupus and their families around the world who have waited more than 52 years for a treatment breakthrough for lupus. We at the LFA applaud the FDA’s decision to approve BENLYSTA®. BENLYSTA is the first drug ever to be specifically developed to treat lupus, and is a significant first step toward reaching our goal of developing an arsenal of new, safe, effective, and tolerable treatments. Today marks the beginning of a new era of improved diagnosis, prevention, and treatment for the disease.
“The LFA wishes to thank the physicians, researchers, industry leaders, and the many study volunteers who made this day possible. We also extend a special thank you to BENLYSTA®’s developers, the staff of Human Genome Sciences and GlaxoSmithKline, who have long been committed to the research and development process. These efforts will go a long way in elevating the profile of this disease that remains a significant national public health problem.
“There are a number of pioneering biotechnology and pharmaceutical companies, involved in the research and development of new treatments for lupus, and our hope is that today’s decision will further stimulate additional companies to invest in new therapies for lupus. To build on this momentum and encourage the development of new treatments, the LFA has launched new initiatives that help to strengthen clinical trials. These programs include the launch of a Web-based program designed to train clinical investigators on the instruments used in trials. As well, the LFA recently implemented the LFA Lupus Research Registry which enables individuals to be notified about new clinical trials in their geographic area. The Registry is part of the LFA’s Center for Clinical Trials Education.
“The LFA also is partnering with key stakeholders from industry, government, and the scientific community to evaluate data from previous lupus clinical trials with the goal to improve the design of future studies."
No comments:
Post a Comment